ASX biotech share rockets 47% on 'landmark decision'

Australia just became the first country to allow ecstasy and magic mushrooms to be used to treat mental disorders.

| More on:
Woman looks amazed and shocked as she looks at her laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Late Friday, Australia became the first country in the world to recognise ecstasy and magic mushrooms as medical treatments.

Officially, the drugs approved for use are 3,4-methylenedioxy-methamphetamine (MDMA) and psilocybin. 

The Therapeutic Goods Administration made the surprise announcement that both would be allowed to be prescribed by psychiatrists from July onwards to treat mental disorders.

The milestone triggered investors to pile onto one particular ASX stock on Monday morning.

'The only ASX company' in position to take advantage of TGA decision

Furious demand saw the share price for neuroscience and mental health biotech Emyria Ltd (ASX: EMD) rocket 47.4% upwards after just 38 minutes of trading on Monday.

The company itself had recognised the TGA announcement before the session, calling it a "landmark" decision in a statement to the ASX.

"Emyria… is well positioned to accelerate patient access to MDMA-assisted therapies following recent TGA regulation changes."

While the TGA was mulling over the decision, Emyria had set up "a network of clinical partners", formed a supply chain and "developed a comprehensive Phase 2B clinical trial protocol for MDMA-assisted therapy".

According to Emyria managing director Dr Michael Winlo, the "mental health crisis" globally continues to bear tremendous social and monetary costs.

"Which is why the TGA's move to reschedule MDMA and psilocybin is timely and world-leading," he said.

"Emyria is well-prepared to support the safe provision of MDMA-assisted therapies under this new change as the only ASX company with a clinical service specialising in unregistered medicines and real-world data generation."

He added that the company has "also developed a comprehensive MDMA-assisted therapy protocol that can now support specialists".

Drug discovery program

Emyria also has fires burning for related products. It has launched an "MDMA-inspired drug discovery" program in conjunction with the University of Western Australia.

"The partnership has now developed, screened and filed IP for over 140 proprietary, neurologically active and novel MDMA-like compounds with the potential to become registered treatments for a range of neuropsychiatric disorders and new psychedelic treatments."

The Emyria board stated that the TGA decision would create a pathway for "registration and reimbursement for MDMA and its analogues".

"We believe the TGA's decision will allow Emyria – and its partners – to build a stronger evidence base for treating mental health conditions with psychedelics and make a large and positive impact for patients globally," said Winlo.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »